Studies on the application of hepatitis B immunoglobulin (HBIG) to HBV-infected pregnant women during late pregnancy showed that: 1. the immunoprophylactic effect on newborns was significantly lower than the accepted protection rate; 2. the diagnostic criteria for mother-to-child transmission of HBV infection were incorrect and the rate of intrauterine HBV infection was exaggerated; 3. the studies had contradictory results for HBV-infected pregnant women themselves before and after control; 4. no anti-HBs were produced in newborns after HBIG was administered to pregnant women. -HBs production. The results of animal experiments showed that the injection of HBIG 200-400 U could not reduce HBV load, and there are no reports in the literature about the reduction of mother-to-child transmission after the use of drugs in pregnant women. Therefore, the use of HBIG in HBV-infected pregnant women during late pregnancy is not necessary.